Abstract Details
Activity Number:
|
324
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 11, 2015 : 8:30 AM to 10:20 AM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #315467
|
View Presentation
|
Title:
|
What Is the Role of Statisticians in Benefit-Risk Adoption Within Our Companies?
|
Author(s):
|
Susan P. Duke* and Greg Anglin
|
Companies:
|
GlaxoSmithKline and Eli Lilly Corporation
|
Keywords:
|
benefit-risk ;
safety ;
QSPI ;
pharmacovigilance
|
Abstract:
|
This talk is based on the efforts of the QSPI Benefit Risk Working Group Best Practice subteam. It will elaborate on the vital contribution of statisticians to the adoption and use of benefit-risk practice within sponsor companies. It will touch on how Benefit-Risk structured thinking and quantification are affecting the drug development/pharmacovigilance process, with a specific focus on the essential role played by statisticians, demonstrating how decision-making is improved by use of structured benefit-risk thinking and quantification.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2015 program
|
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.